METTL3 and nasopharyngeal carcinoma: As shown in Figure 3A, the NPC patients with high expression of IGF2BP1 (HR = 1.307, 95% CI = 1.119–1.526) and IGF2BP2 (HR = 1.061, 95% CI = 1.002–1.124) and low expression of METTL3 (HR = 0.854, 95% CI = 0.726–0.957) have a poor prognosis.